Motor Impairments, Striatal Degeneration, and Altered Dopamine-Glutamate Interplay in Mice Lacking PSD-95

REFERENCES

• Aarts, M., Liu, Y., Liu, L., Besshoh, S., Arundine, M., Gurd, J. W., Wang, Y. T., Salter, M. W., & Tymianski, M. (2002). Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions. Science, 298, 846–850.
   PubMed Web of Science ®Google Scholar
• Abbas, A. I., Yadav, P. N., Yao, W. D., Arbuckle, M. I., Grant, S. G., Caron, M. G., & Roth, B. L. (2009). PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci, 29, 7124–7136.
   PubMed Web of Science ®Google Scholar
• Albin, R. L., Young, A. B., Penney, J. B., Handelin, B., Balfour, R., Anderson, K. D., Markel, D. S., Tourtellotte, W. W., & Reiner, A. (1990). Abnormalities of striatal projection neurons and N-methyl-d-aspartate receptors in presymptomatic Huntington's disease. N Engl J Med, 322, 1293–1298.
   PubMed Web of Science ®Google Scholar
• Allbutt, H. N., & Henderson, J. M. (2007). Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease. J Neurosci Methods, 159, 195–202.
   PubMedGoogle Scholar
• Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986). Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature, 321, 168–171.
   PubMed Web of Science ®Google Scholar
• Beique, J. C., Lin, D. T., Kang, M. G., Aizawa, H., Takamiya K., & Huganir, R. L. (2006). Synapse-specific regulation of AMPA receptor function by PSD-95. Proc Natl Acad Sci U S A, 103, 19535–19540.
   PubMedGoogle Scholar
• Bozzi, Y., & Borrelli, E. (2006). Dopamine in neurotoxicity and neuroprotection: What do D2 receptors have to do with it?Trends Neurosci, 29, 167–174.
   PubMed Web of Science ®Google Scholar
• Brenman, J. E., Chao, D. S., Gee, S. H., McGee, A. W., Craven, S. E., Santillano, D. R., Wu, Z., Huang, F., Xia, H., Peters, M. F., Froehner, S. C., & Bredt, D. S. (1996). Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell, 84, 757–767.
   PubMed Web of Science ®Google Scholar
• Camp, M. C., Feyder, M., Ihne, J., Palachick, B., Hurd, B., Karlsson, R. M., Noronha, B., Chen, Y. C., Coba, M. P., Grant, S. G., & Holmes, A. (2011). A novel role for PSD-95 in mediating ethanol intoxication, drinking and place preference. Addict Biol, 16, 428–439.
   PubMedGoogle Scholar
• Carr, D. B., & Sesack, S. R. (1996). Hippocampal afferents to the rat prefrontal cortex: Synaptic targets and relation to dopamine terminals. J Comp Neurol, 369, 1–15.
   PubMedGoogle Scholar
• Cepeda, C., & Levine, M. S. (2006). Where do you think you are going? The NMDA-D1 receptor trap. Sci STKE, 2006, pe20.
   Google Scholar
• Cha, J. H. (2007). Transcriptional signatures in Huntington's disease. Prog Neurobiol, 83, 228–248.
   PubMed Web of Science ®Google Scholar
• Choi, D. W. (1988). Glutamate neurotoxicity and diseases of the nervous system. Neuron, 1, 623–634.
   PubMed Web of Science ®Google Scholar
• Cyr, M., Beaulieu, J. M., Laakso, A., Sotnikova, T. D., Yao, W. D., Bohn, L. M., Gainetdinov, R. R., & Caron, M. G. (2003). Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci U S A, 100, 11035–11040.
   PubMed Web of Science ®Google Scholar
• Cyr, M., Sotnikova, T. D., Gainetdinov, R. R., & Caron, M. G. (2006). Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB J, 20, 2541–2543.
   PubMedGoogle Scholar
• Dragatsis, I., Levine, M. S., & Zeitlin, S. (2000). Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet, 26, 300–306.
   PubMed Web of Science ®Google Scholar
• El-Husseini, A. E., Schnell, E., Chetkovich, D. M., Nicoll, R. A., & Bredt, D. S. (2000). PSD-95 involvement in maturation of excitatory synapses. Science, 290, 1364–1368.
   PubMed Web of Science ®Google Scholar
• Elias, G. M., Funke, L., Stein, V., Grant, S. G., Bredt D. S., & Nicoll, R. A. (2006). Synapse-specific and developmentally regulated targeting of AMPA receptors by a family of MAGUK scaffolding proteins. Neuron, 52, 307–320.
   PubMedGoogle Scholar
• Fan, M. M., & Raymond, L. A. (2007). N-methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol, 81, 272–293.
   PubMed Web of Science ®Google Scholar
• Fiorentini, C., Rizzetti, M. C., Busi, C., Bontempi, S., Collo, G., Spano, P., & Missale, C. (2006). Loss of synaptic D1 dopamine/N-methyl-d-aspartate glutamate receptor complexes in l-DOPA-induced dyskinesia in the rat. Mol Pharmacol, 69, 805–812.
   PubMed Web of Science ®Google Scholar
• Freund, T. F., Powell, J. F., & Smith, A. D. (1984). Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience, 13, 1189–1215.
   PubMed Web of Science ®Google Scholar
• Futai, K., Kim, M. J., Hashikawa, T., Scheiffele, P., Sheng, M., & Hayashi, Y. (2007). Retrograde modulation of presynaptic release probability through signaling mediated by PSD-95-neuroligin. Nat Neurosci, 10, 186–195.
   PubMedGoogle Scholar
• Gardoni, F. (2008). MAGUK proteins: New targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol, 585, 147–152.
   Google Scholar
• Gardoni, F., Bellone, C., Viviani, B., Marinovich, M., Meli, E., Pellegrini-Giampietro D. E., Cattabeni, F., & Di Luca M. (2002). Lack of PSD-95 drives hippocampal neuronal cell death through activation of an alpha CaMKII transduction pathway. Eur J Neurosci, 16, 777–786.
   PubMed Web of Science ®Google Scholar
• Gardoni, F., Picconi, B., Ghiglieri, V., Polli, F., Bagetta, V., Bernardi, G., Cattabeni, F., Di Luca M., & Calabresi, P. (2006). A critical interaction between NR2B and MAGUK in l-DOPA induced dyskinesia. J Neurosci, 26, 2914–2922.
   PubMed Web of Science ®Google Scholar
• Gerfen, C. R. (1992). The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia. Annu Rev Neurosci, 15, 285–320.
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic P. S., Leranth, C., Williams, S. M., Mons, N., & Geffard, M. (1989). Dopamine synaptic complex with pyramidal neurons in primate cerebral cortex. Proc Natl Acad Sci U S A, 86, 9015–9019.
   PubMed Web of Science ®Google Scholar
• Ha, C. M., Park, D., Han, J. K., Jang, J. I., Park, J. Y., Hwang, E. M., Seok, H., & Chang, S. (2012). Calcyon forms a novel ternary complex with dopamine D1 receptor through PSD-95 protein and plays a role in dopamine receptor internalization. J Biol Chem, 287, 31813–31822.
   PubMedGoogle Scholar
• Hantraye, P., Riche, D., Maziere, M., & Isacson, O. (1990). A primate model of Huntington's disease: Behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol, 108, 91–104.
   PubMedGoogle Scholar
• Hardingham, G. E., & Bading, H. (2002). Coupling of extrasynaptic NMDA receptors to a CREB shut-off pathway is developmentally regulated. Biochim Biophys Acta, 1600, 148–153.
   PubMed Web of Science ®Google Scholar
• Hersch, S. M., Ciliax, B. J., Gutekunst, C. A., Rees, H. D., Heilman, C. J., Yung, K. K., Bolam, J. P., Ince, E., Yi, H., & Levey, A. I. (1995). Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J Neurosci, 15, 5222–5237.
   PubMed Web of Science ®Google Scholar
• Jarabek, B. R., Yasuda, R. P., & Wolfe, B. B. (2004). Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain, 127, 505–516.
   PubMed Web of Science ®Google Scholar
• Kihara, T., Shimohama, S., Sawada, H., Honda, K., Nakamizo, T., Kanki, R., Yamashita, H., & Akaike, A. (2002). Protective effect of dopamine D2 agonists in cortical neurons via the phosphatidylinositol 3 kinase cascade. J Neurosci Res, 70, 274–282.
   PubMedGoogle Scholar
• Kim, E., & Sheng, M. (2004). PDZ domain proteins of synapses. Nat Rev Neurosci, 5, 771–781.
   PubMed Web of Science ®Google Scholar
• Kruusmagi, M., Kumar, S., Zelenin, S., Brismar, H., Aperia, A., & Scott, L. (2009). Functional differences between D(1) and D(5) revealed by high resolution imaging on live neurons. Neuroscience, 164, 463–469.
   PubMedGoogle Scholar
• Levine, M. S., Cepeda, C., Hickey, M. A., Fleming, S. M., & Chesselet, M. F. (2004). Genetic mouse models of Huntington's and Parkinson's diseases: Illuminating but imperfect. Trends Neurosci, 27, 691–697.
   PubMedGoogle Scholar
• Levine, M. S., Klapstein, G. J., Koppel, A., Gruen, E., Cepeda, C., Vargas, M. E., Jokel, E. S., Carpenter, E. M., Zanjani, H., Hurst, R. S., Efstratiadis, A., Zeitlin, S., & Chesselet, M. F. (1999). Enhanced sensitivity to N-methyl-d-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res, 58, 515–532.
   PubMed Web of Science ®Google Scholar
• Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., & Bates, G. P. (1996). Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493–506.
   PubMed Web of Science ®Google Scholar
• Mantamadiotis, T., Lemberger, T., Bleckmann, S. C., Kern, H., Kretz, O., Martin Villalba A., Tronche, F., Kellendonk, C., Gau, D., Kapfhammer, J., Otto, C., Schmid, W., & Schutz, G. (2002). Disruption of CREB function in brain leads to neurodegeneration. Nat Genet, 31, 47–54.
   PubMed Web of Science ®Google Scholar
• Migaud, M., Charlesworth, P., Dempster, M., Webster, L. C., Watabe, A. M., Makhinson, M., He, Y., Ramsay, M. F., Morris, R. G., Morrison, J. H., O’Dell T. J., & Grant, S. G. (1998). Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature, 396, 433–439.
   PubMed Web of Science ®Google Scholar
• Milnerwood, A. J., & Raymond, L. A. (2010). Early synaptic pathophysiology in neurodegeneration: Insights from Huntington's disease. Trends Neurosci, 33, 513–523.
   PubMed Web of Science ®Google Scholar
• Nash, J. E., Johnston, T. H., Collingridge, G. L., Garner, C. C., & Brotchie, J. M. (2005). Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and l-DOPA-induced dyskinesia. FASEB J, 19, 583–585.
   PubMed Web of Science ®Google Scholar
• Paxinos, G., & Franklin, K. B. J. (2001). The mouse brain in stereotaxic coordinates (4th ed.). San Diego: Academic Press.
   Google Scholar
• Porras, G., Berthet, A., Dehay, B., Li, Q., Ladepeche, L., Normand, E., Dovero, S., Martinez, A., Doudnikoff, E., Martin-Negrier M. L., Chuan, Q., Bloch, B., Choquet, D., Boue-Grabot E., Groc, L., & Bezard, E. (2012). PSD-95 expression controls l-DOPA dyskinesia through dopamine D1 receptor trafficking. J Clin Invest, 122, 3977–3989.
   PubMedGoogle Scholar
• Reddy, P. H., Williams, M., Charles, V., Garrett, L., Pike-Buchanan L., Whetsell, W. O., Jr., Miller, G., & Tagle, D. A. (1998). Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet, 20, 198–202.
   PubMed Web of Science ®Google Scholar
• Riccio, A., & Ginty, D. D. (2002). What a privilege to reside at the synapse: NMDA receptor signaling to CREB. Nat Neurosci, 5, 389–390.
   PubMed Web of Science ®Google Scholar
• Rumbaugh, G., & Vicini, S. (1999). Distinct synaptic and extrasynaptic NMDA receptors in developing cerebellar granule neurons. J Neurosci, 19, 10603–10610.
   PubMedGoogle Scholar
• Sattler, R., Xiong, Z., Lu, W. Y., Hafner, M., MacDonald, J. F., & Tymianski, M. (1999). Specific coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein. Science, 284, 1845–1848.
   PubMed Web of Science ®Google Scholar
• Seamans, J. K., Durstewitz, D., Christie, B. R., Stevens, C. F., & Sejnowski, T. J. (2001). Dopamine D1/D5 receptor modulation of excitatory synaptic inputs to layer V prefrontal cortex neurons. Proc Natl Acad Sci U S A, 98, 301–306.
   PubMed Web of Science ®Google Scholar
• Stanley, J. L., Lincoln, R. J., Brown, T. A., McDonald, L. M., Dawson, G. R., & Reynolds, D. S. (2005). The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines. J Psychopharmacol, 19, 221–227.
   PubMed Web of Science ®Google Scholar
• Sun, P., Wang, J., Gu, W., Cheng, W., Jin, G. Z., Friedman, E., Zheng, J., & Zhen, X. (2009). PSD-95 regulates D1 dopamine receptor resensitization, but not receptor-mediated Gs-protein activation. Cell Res, 19, 612–624.
   PubMedGoogle Scholar
• Sun, Y., Savanenin, A., Reddy, P. H., & Liu, Y. F. (2001). Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-d-aspartate receptors via post-synaptic density 95. J Biol Chem, 276, 24713–24718.
   PubMed Web of Science ®Google Scholar
• The Huntington's Disease Collaborative Research Group. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971–983.
   PubMed Web of Science ®Google Scholar
• West, M. J. (1993). New stereological methods for counting neurons. Neurobiol Aging, 14, 275–285.
   PubMed Web of Science ®Google Scholar
• West, M. J., & Gundersen, H. J. (1990). Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol, 296, 1–22.
   PubMed Web of Science ®Google Scholar
• Yamada, Y., Chochi, Y., Ko, J. A., Sobue, K., & Inui, M. (1999). Activation of channel activity of the NMDA receptor-PSD-95 complex by guanylate kinase-associated protein (GKAP). FEBS Lett, 458, 295–298.
   PubMedGoogle Scholar
• Yamamoto, A., Lucas, J. J., & Hen, R. (2000). Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell, 101, 57–66.
   PubMed Web of Science ®Google Scholar
• Yao, W. D., Gainetdinov, R. R., Arbuckle, M. I., Sotnikova, T. D., Cyr, M., Beaulieu, J. M., Torres, G. E., Grant, S. G., & Caron, M. G. (2004). Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron, 41, 625–638.
   PubMed Web of Science ®Google Scholar
• Yao, W. D., Spealman, R. D., & Zhang, J. (2008). Dopaminergic signaling in dendritic spines. Biochem Pharmacol, 75, 2055–2069.
   PubMedGoogle Scholar
• Young, A. B., Greenamyre, J. T., Hollingsworth, Z., Albin, R., D’Amato C., Shoulson, I., & Penney, J. B. (1988). NMDA receptor losses in putamen from patients with Huntington's disease. Science, 241, 981–983.
   PubMed Web of Science ®Google Scholar
• Zeron, M. M., Hansson, O., Chen, N., Wellington, C. L., Leavitt, B. R., Brundin, P., Hayden, M. R., & Raymond, L. A. (2002). Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron, 33, 849–860.
   PubMed Web of Science ®Google Scholar
• Zhang, J., Vinuela, A., Neely, M. H., Hallett, P. J., Grant, S. G., Miller, G. M., Isacson, O., Caron, M. G., & Yao, W. D. (2007). Inhibition of the dopamine D1 receptor signaling by PSD-95. J Biol Chem, 282, 15778–15789.
   PubMed Web of Science ®Google Scholar
• Zhang, J., Xu, T. X., Hallett, P. J., Watanabe, M., Grant, S. G., Isacson, O., & Yao, W. D. (2009). PSD-95 uncouples dopamine-glutamate interaction in the D1/PSD-95/NMDA receptor complex. J Neurosci, 29, 2948–2960.
   PubMed Web of Science ®Google Scholar
• Zucker, B., Luthi-Carter R., Kama, J. A., Dunah, A. W., Stern, E. A., Fox, J. H., Standaert, D. G., Young, A. B., & Augood, S. J. (2005). Transcriptional dysregulation in striatal projection and interneurons in a mouse model of Huntington's disease: Neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet, 14, 179–189.
   PubMedGoogle Scholar